Imarsa (Fulvestrant)

Fulvestrant acts on estrogen‑dependent breast cancer pathways and is indicated for the following conditions:

• Hormone receptor‑positive metastatic breast cancer: delays disease progression and improves survival.
• Postmenopausal estrogen receptor‑positive advanced breast cancer: used after progression on prior endocrine therapy.
• Advanced breast cancer after aromatase‑inhibitor failure: provides an alternative hormonal treatment option.

• Fulvestrant binds competitively to estrogen receptors (ERα and ERβ) with high affinity, blocking estrogen‑mediated transcription. The drug also induces a conformational change that targets the receptor for proteasomal degradation, leading to down‑regulation of ER levels and inhibition of estrogen‑driven tumor cell proliferation.

Fulvestrant may cause a range of adverse reactions.

Common Side Effects

• Injection site pain: discomfort at the intramuscular injection site.
• Hot flashes: transient episodes of warmth and sweating.
• Nausea: mild to moderate upset stomach.
• Fatigue: generalized tiredness.
• Headache: mild to moderate intensity.
• Musculoskeletal pain: aches in joints or muscles.

Serious or Rare Side Effects

• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Pulmonary embolism: sudden shortness of breath or chest pain.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Tumor pain flare: worsening of cancer‑related pain.
• Hyperglycemia: increased blood glucose levels.
• Thrombocytopenia: reduced platelet count.

When prescribing or handling Fulvestrant, consider the following precautions:

• Monitor liver function: obtain baseline and periodic liver enzyme tests.
• Assess thromboembolic risk: evaluate history of clotting disorders before use.
• Evaluate hypersensitivity: discontinue if signs of severe allergic reaction appear.
• Avoid in uncontrolled infection: postpone treatment until infection is resolved.
• Pregnancy considerations: safety unknown; avoid use in pregnant women.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fulvestrant may interact with other medicines.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce fulvestrant exposure.
• Concurrent estrogen therapy: can antagonize fulvestrant’s anti‑estrogen effect.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Other SERDs or hormonal agents: may increase toxicity risk.